AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2884410 — intervention group
Group type: COMPARATOR
Intervention: Non-immunised controls
Number of subjects: 15
Study 29098900 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 53
Study 29098900 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% topical spray
Number of subjects: 53
Study 29098900 — intervention group
Group type: COMPARATOR
Intervention: Vehicle topical spray
Number of subjects: 53
Study 27026570 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE in dry land
Number of subjects: 42
Study 27026570 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE in immersed condition
Number of subjects: 42
Study 27026570 — intervention group
Group type: COMPARATOR
Intervention: MICE
Number of subjects: 42
Study 22633317 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 643
Study 22633317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 22889095 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNano 10 mg/kg
Number of subjects: 144
Study 22889095 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNano 20 mg/kg
Number of subjects: 144
Study 22889095 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/kg AgNano)
Number of subjects: 144
Study 20214066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Zusanli (ST 36), Pishu (BL 20), Weishu (BL 21)
Number of subjects: 300
Study 20214066 — intervention group
Group type: COMPARATOR
Intervention: Lysine Dicalcium Phosphate particles (Control)
Number of subjects: 300
Study 20214066 — intervention group
Group type: COMPARATOR
Intervention: Flour capsule (Placebo)
Number of subjects: 300
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: n Power (implicit power motivation)
Number of subjects: 49
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: n Power with contest outcome (win vs. loss)
Number of subjects: 49
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: n Power in power-motivated winners
Number of subjects: 49
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: n Power and estradiol
Number of subjects: 49
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dominance and aggression
Number of subjects: 49
Study 17949722 — intervention group
Group type: EXPERIMENTAL
Intervention: n Power
Number of subjects: 49
Study 16243090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethoate
Number of subjects: 802
Study 16243090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenthion
Number of subjects: 802
Study 16243090 — intervention group
Group type: COMPARATOR
Intervention: Chlorpyrifos
Number of subjects: 802
Study 12067837 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion alone
Number of subjects: 16
Study 12067837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus lipid/heparin infusion
Number of subjects: 16
Study 10661828 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 64
Study 10661828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8886540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 0.5 percent shampoo
Number of subjects: 78
Study 8886540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 1 percent shampoo
Number of subjects: 78
Study 8886540 — intervention group
Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 78
Study 1898641 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) therapy
Number of subjects: 376
Study 6306038 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF (0.3 micrograms/kg BW)
Number of subjects: 13
Study 6306038 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF (3 micrograms/kg BW)
Number of subjects: 13
Study 6306038 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF (30 micrograms/kg BW)
Number of subjects: 13
Study 6306038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30121470 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation (DNAm) in blood
Number of subjects: 0
Study 30121470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0
Study 30121470 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between social scientists, health methodologists, and basic scientists
Number of subjects: 0
Study 27930497 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + DM (30 mg/d)
Number of subjects: 309
Study 27930497 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + DM (60 mg/d)
Number of subjects: 309
Study 27930497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 26869049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m² (reduced to 125 mg/m² after 464 participants)
Number of subjects: 1206
Study 26869049 — intervention group
Group type: COMPARATOR
Intervention: Solvent-based paclitaxel 80 mg/m²
Number of subjects: 1206
Study 26869049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Number of subjects: 1206
Study 25389139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (HS) administered 6-hourly
Number of subjects: 317
Study 25389139 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 317
Study 25389139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (HS)
Number of subjects: 317
Study 22309791 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Analog Risk Task (BART)
Number of subjects: 79
Study 22309791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous drinking assessment with AUDIT
Number of subjects: 79
Study 19486466 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride varnish three times per school year
Number of subjects: 0
Study 19486466 — intervention group
Group type: COMPARATOR
Intervention: Varnish plus twice‐per‐day toothbrushing and xylitol containing gummy bear snacks
Number of subjects: 0
Study 17894710 — intervention group
Group type: COMPARATOR
Intervention: 6 J/cm² without CAC
Number of subjects: 11
Study 17894710 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 J/cm² with CAC (level 4)
Number of subjects: 11
Study 17894710 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 J/cm² with CAC (level 4)
Number of subjects: 11
Study 16079640 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin, 40 mg daily
Number of subjects: 28
Study 16079640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild endurance exercise training (three or more times a week)
Number of subjects: 28
Study 10770301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin 100 IU/kg subcutaneously twice a day)
Number of subjects: 449
Study 10770301 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (160 mg every day)
Number of subjects: 449
Study 10770301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 449
Study 10770301 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 449
Study 9410771 — intervention group
Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 32
Study 9410771 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI mode
Number of subjects: 32
Study 9410771 — intervention group
Group type: COMPARATOR
Intervention: DDD mode in patients with retroconduction
Number of subjects: 32
Study 9410771 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI mode in patients with retroconduction
Number of subjects: 32
Study 9410771 — intervention group
Group type: COMPARATOR
Intervention: DDD mode in patients without retroconduction
Number of subjects: 32
Study 9410771 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI mode in patients without retroconduction
Number of subjects: 32
Study 9410771 — intervention group
Group type: COMPARATOR
Intervention: DVI stimulation during DDD mode
Number of subjects: 32
Study 9410771 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD stimulation during DDD mode
Number of subjects: 32
Study 8447210 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupoint injection with 0.2 ml 50% glucose in water
Number of subjects: 120
Study 8447210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 20 micrograms/kg droperidol
Number of subjects: 120
Study 8447210 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 120
Study 3753988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 153
Study 3753988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 153
Study 3753988 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 153
Study 3753988 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 153
Study 3753988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 2908235 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg D-fenfluramine
Number of subjects: 29
Study 2908235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study 30946442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 10 mg/kg every 6 hours for the first 9 postoperative days
Number of subjects: 741
Study 30946442 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen, 15 mg/kg every 6 hours for the first 9 postoperative days
Number of subjects: 741
Study 28138803 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in primary care (PCP)
Number of subjects: 3152
Study 28138803 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in specialist care
Number of subjects: 3152
Study 28138803 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in PCP
Number of subjects: 3152
Study 26173613 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0
Study 26173613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23187164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (5 mg/mL) 4 times daily for 2 months
Number of subjects: 44
Study 23187164 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear 4 times daily for 2 months
Number of subjects: 44
Study 21996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655
Study 21996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fascial sling
Number of subjects: 655
Study 21996108 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical failures)
Number of subjects: 655
Study 18808333 — intervention group
Group type: EXPERIMENTAL
Intervention: rBCG30
Number of subjects: 35
Study 18808333 — intervention group
Group type: COMPARATOR
Intervention: Tice BCG
Number of subjects: 35
Study 16546766 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (7 group sessions over 7 weeks)
Number of subjects: 37
Study 16546766 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (average of 11 individual sessions over 20 weeks)
Number of subjects: 37
Study 12836580 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT); specific treatment strategies targeting relational ruptures and rebuilding relationships; details on dosage and duration not available.
Number of subjects: 0
Study 10679658 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (Arm A)
Number of subjects: 100
Study 10679658 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (Arm B)
Number of subjects: 100
Study 9538431 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational project intervention in nursery schools, involving awareness-raising among families and teaching tools distributed by community physicians over 2 years.
Number of subjects: 1500
Study 8418228 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan/prednisone
Number of subjects: 278
Study 8418228 — intervention group
Group type: COMPARATOR
Intervention: Melphalan/prednisone/interferon alfa-2b
Number of subjects: 278
Study 2430797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (2.5 ml in 8% dextrose)
Number of subjects: 60
Study 2430797 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric 0.5% cinchocaine (1.5 ml in 6% dextrose)
Number of subjects: 60
Study 31266717 — intervention group
Group type: EXPERIMENTAL
Intervention: tRNS (real session)
Number of subjects: 32
Study 31266717 — intervention group
Group type: COMPARATOR
Intervention: Sham session
Number of subjects: 32
Study 28770527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 36
Study 28770527 — intervention group
Group type: COMPARATOR
Intervention: Person-centred counselling
Number of subjects: 36
Study 26426664 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 9256
Study 26426664 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 9256
Study 26426664 — intervention group
Group type: COMPARATOR
Intervention: Macrolide + β-lactam
Number of subjects: 9256
Study 26426664 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam alone
Number of subjects: 9256
Study 23507136 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion version of the Clinical Interview Schedule (CIS-R)
Number of subjects: 277
Study 23507136 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 277
Study 23507136 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 277
Study 23507136 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered Clinical Interview Schedule (CIS-R)
Number of subjects: 277
Study 23507136 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion version of the CIS-R
Number of subjects: 277
Study 21264830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 158
Study 21264830 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 158
Study 18287591 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0.05 mg/kg)
Number of subjects: 57
Study 18287591 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1 mg)
Number of subjects: 57
Study 18287591 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (50 microg)
Number of subjects: 57
Study 18287591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine chloride (100 microg)
Number of subjects: 57
Study 16572442 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 1084
Study 16572442 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 1084
Study 16572442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study 14583341 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily of purified eicosapentaenoic acid (EPA) for 6 weeks
Number of subjects: 59
Study 14583341 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily of docosahexaenoic acid (DHA) for 6 weeks
Number of subjects: 59
Study 14583341 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control) for 6 weeks
Number of subjects: 59
Study 11177158 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/d of recombinant follicle‐stimulating hormone
Number of subjects: 40
Study 11177158 — intervention group
Group type: COMPARATOR
Intervention: 200 IU/d of recombinant follicle‐stimulating hormone
Number of subjects: 40
Study 9226493 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable meal (Ensure, 1048 KJ, 450 ml)
Number of subjects: 43
Study 9226493 — intervention group
Group type: COMPARATOR
Intervention: Unpalatable meal (Ensure with aqueous KCl)
Number of subjects: 43
Study 9226493 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold for unpleasant taste of KCl
Number of subjects: 43
Study 8408914 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 700
Study 8408914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy of reticular veins
Number of subjects: 700
Study 2878811 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 45
Study 2878811 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 45
Study 2878811 — intervention group
Group type: EXPERIMENTAL
Intervention: both terfenadine and ranitidine
Number of subjects: 45
Study 2878811 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine and ranitidine
Number of subjects: 45
Study 29789365 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 450
Study 29789365 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC (Traditional Chinese Herbal Formula)
Number of subjects: 450
Study 28147254 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 85
Study 25572450 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system
Number of subjects: 0
Study 25572450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23974915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 345
Study 23974915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus laser
Number of subjects: 345
Study 23974915 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 345
Study 20048683 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g rPC daily
Number of subjects: 40
Study 20048683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g rPC daily
Number of subjects: 40
Study 20048683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g rPC daily
Number of subjects: 40
Study 20048683 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g rPC daily
Number of subjects: 40
Study 18419402 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ vaccine
Number of subjects: 38546
Study 16612277 — intervention group
Group type: EXPERIMENTAL
Intervention: C0 monitoring of cyclosporine (CsA)
Number of subjects: 160
Study 16612277 — intervention group
Group type: COMPARATOR
Intervention: C2 monitoring of cyclosporine (CsA)
Number of subjects: 160
Study 14562520 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive short-term group therapy
Number of subjects: 107
Study 14562520 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive short-term group therapy
Number of subjects: 107
Study 11105068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 24
Study 11105068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8900613 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises (progressive muscle relaxation, meditative breathing, guided imagery, soft music)
Number of subjects: 39
Study 1839644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CBD (10 mg/kg/day for 6 weeks)
Number of subjects: 15
Study 1839644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame oil for 6 weeks)
Number of subjects: 15
Study 6623221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane as a volatile supplement to nitrous oxide anesthesia
Number of subjects: 107
Study 6623221 — intervention group
Group type: COMPARATOR
Intervention: Halothane as a volatile supplement to nitrous oxide anesthesia
Number of subjects: 107
Study 30189282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 914
Study 30189282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 914
Study 30189282 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 914
Study 28138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Open left lateral sectionectomy (OLLS)
Number of subjects: 24
Study 28138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic left lateral sectionectomy (LLLS)
Number of subjects: 24
Study 28138958 — intervention group
Group type: COMPARATOR
Intervention: Open non-randomized (ONR)
Number of subjects: 24
Study 28138958 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic non-randomized (LNR)
Number of subjects: 24
Study 28138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 24
Study 26030174 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about future selves
Number of subjects: 0
Study 26030174 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about past selves
Number of subjects: 0
Study 23473527 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg BID for 4 weeks, then 10 μg BID for 12 weeks
Number of subjects: 50
Study 23473527 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 50
Study 22611676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (100 mg intramuscular for 10 days, then 125 mg orally three times a day for 20 days)
Number of subjects: 40
Study 22611676 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (Diroton 5-20 mg daily, Cardiomagnyl 75 mg daily)
Number of subjects: 40
Study 19256262 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon (25000 U)
Number of subjects: 32
Study 19256262 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon (25 or 50% higher dose)
Number of subjects: 32
Study 17451693 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian diathermy
Number of subjects: 0
Study 17451693 — intervention group
Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian diathermy
Number of subjects: 0
Study 15094530 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercises
Number of subjects: 81
Study 15094530 — intervention group
Group type: COMPARATOR
Intervention: Individualized physical therapy without specific stabilizing exercises
Number of subjects: 81
Study 12964233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydropolymer dressing
Number of subjects: 113
Study 12964233 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 113
Study 10214426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (treatment group)
Number of subjects: 110
Study 10214426 — intervention group
Group type: COMPARATOR
Intervention: Group A (no treatment)
Number of subjects: 110